← Leaderboards
David Bisagaya Meya
Infectious Diseases Institute
$12,205,470
Attributed
$23,944,446
Total exposure
11
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,556,418 · 10
CDC$1,388,028 · 1
By mechanism
R01$13,483,506 · 5
U01$4,767,357 · 2
RF1$3,032,667 · 1
UG3$2,145,116 · 1
D43$498,800 · 1
R13$17,000 · 1
Top collaborators
- David R Boulware28 shared
- Kirsten Nielsen6 shared
- Joel Bazira5 shared
- Andrew Ddungu Kambugu4 shared
- Nathan Bahr2 shared
Others in their field
Top investigators on “Uganda”
- Diane V Havlir · University Of California, San Francisco$86,138,992
- Mary Glenn Fowler · Johns Hopkins University$48,391,343
- Myron S Cohen · Family Health International$36,604,553
- Christopher C. Whalen · Case Western Reserve University$30,266,640
- Philip Jon Rosenthal · University Of California San Francisco$29,418,609
- Ronald H Gray · Johns Hopkins University$29,290,853
Research focus
UgandaAcquired Immunodeficiency SyndromeMeningitisMortalityPersonsCryptococcal MeningitisMorbidity - Disease RateCessation Of LifeAfrica South Of The SaharaAfricaCaringCryptococcusInfectionAntiretroviral TherapyBrainInnovationAdultDiagnosisCryptococcosisFluconazoleProspectiveClinical ResearchLaboratoriesMycoses
Grant awards (43)
Understanding the causes of second episode cryptococcal meningitis to improve diagnosis and treatment$1,841,519
RF1 · FY2025 · NS
Understanding the causes of second episode cryptococcal meningitis to improve diagnosis and treatment$1,191,148
RF1 · FY2025 · NS
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies$645,211
R01 · FY2025 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$332,546
R01 · FY2025 · NS
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$297,733
R01 · FY2025 · NS
Minnesota-Makerere-Mbarara Neuro-Infectious Disease Research Training Consortium$248,400
D43 · FY2025 · TW
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies$649,938
R01 · FY2024 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$644,029
R01 · FY2024 · NS
Genomic Research Capacity Building for Cryptococcosis Translational Studies$552,587
R01 · FY2024 · NS
Minnesota-Makerere-Mbarara Neuro-Infectious Disease Research Training Consortium$250,400
D43 · FY2024 · TW
Encochleated Oral Amphotericin for HIV-related Cryptococcal Meningitis Trial: Phase 3 Trial$2,145,116
UG3 · FY2023 · NS
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies$660,699
R01 · FY2023 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$620,692
R01 · FY2023 · NS
Genomic Research Capacity Building for Cryptococcosis Translational Studies$552,587
R01 · FY2023 · NS
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies$670,820
R01 · FY2022 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$626,250
R01 · FY2022 · NS
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial$625,976
R01 · FY2022 · NS
Genomic Research Capacity Building for Cryptococcosis Translational Studies$552,587
R01 · FY2022 · NS
11th International Conference on Cryptococcus and Cryptococcosis (ICCC)$17,000
R13 · FY2022 · AI
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies$696,169
R01 · FY2021 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$632,702
R01 · FY2021 · NS
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial$632,233
R01 · FY2021 · NS
Genomic Research Capacity Building for Cryptococcosis Translational Studies$526,621
R01 · FY2021 · NS
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$670,413
U01 · FY2020 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$638,208
R01 · FY2020 · NS
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial$637,925
R01 · FY2020 · NS
Genomic Research Capacity Building for Cryptococcosis Translational Studies$563,218
R01 · FY2020 · NS
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$129,417
U01 · FY2020 · AI
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial$654,844
R01 · FY2019 · NS
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis$654,844
R01 · FY2019 · NS
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$649,661
U01 · FY2019 · AI
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$116,551
U01 · FY2019 · AI
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$508,514
U01 · FY2018 · AI
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)$646,880
U01 · FY2017 · AI
Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV Patients$657,893
U01 · FY2016 · AI
Operational Research for cryptococcal antigen screening to improve ART survival$414,281
U01 · FY2014 · GH · contact PI
GH11-005, Uganda: Operational Research for cryptococcal antigen screening to improve ART survival$485,309
U01 · FY2013 · GH · contact PI
The immunopathogenesis of HIV-related Immune Reconstitution Inflammatory Syndrome$98,495
R01 · FY2013 · AI · contact PI
GH11-005, Uganda: Operational Research for cryptococcal antigen screening to improve ART survival$14
U01 · FY2013 · GH · contact PI
Operational Research for cryptococcal antigen screening to improve ART survival$488,424
U01 · FY2012 · GH · contact PI
The immunopathogenesis of HIV-related Immune Reconstitution Inflammatory Syndrome$104,782
R01 · FY2012 · AI · contact PI
The immunopathogenesis of HIV-related Immune Reconstitution Inflammatory Syndrome$103,810
R01 · FY2011 · AI · contact PI
The immunopathogenesis of HIV-related Immune Reconstitution Inflammatory Syndrome$108,000
R01 · FY2010 · AI · contact PI